THE AIM OF THE STUDY

Was to evaluate the clinical efficacy of parodontax Comprehensive Protection (GlaxoSmithKline, London, UK) toothpaste in the complex therapy of chronic gingivitis.

MATERIALS AND METHODS

The study involved 119 volunteers; group 1 (n=59, age range 18 to 32 years) and group 2 (n=60, age range 20 to 35 years) with a diagnosis of chronic gingivitis (K05.1). The criterion for inclusion in the study was sulcus bleeding index (SBI) more than 1 point. Dental examination included SBI, papillary-marginal-alveolar index (PMA), and Green-Vermillion oral hygiene index (OHI-S). After determining the indices, all patients underwent professional oral hygiene and controlled tooth cleaning. Patients in group 1 (parodontax) were prescribed parodontax Comprehensive Protection toothpaste (GlaxoSmithKline, London, UK), patients in group 2 — a toothpaste that did not contain sodium bicarbonate. Repeated clinical examinations with the determination of the SBI, PMA, OHI-S were carried out after week 2 and 4.

RESULTS

After 4 weeks, SBI scores in group 1 were 63% lower than at baseline, and in group 2 — by 30%. PMA values at 4 weeks in group 1 were 58% and in group 2 30% lower, compared to baseline levels. The results of the analysis of the OHI-S index showed a statistically significant decrease in group 1 by 75%, while in group 2 by only 8% from the initial values. The difference in all index values between groups at 4 weeks of the study was statistically significant (p<0.05).

CONCLUSION

The use of parodontax Comprehensive Protection Toothpaste (GlaxoSmithKline, London, UK) has been shown to reduce the clinical signs of biofilm-associated gingivitis and effectively maintain optimal oral hygiene in patients.